Teodozyj Kolasa
Overview
Explore the profile of Teodozyj Kolasa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel M, Kolasa T, Mortell K, Matulenko M, Hakeem A, Rohde J, et al.
J Med Chem
. 2006 Dec;
49(25):7450-65.
PMID: 17149874
The goal of this study was to identify a structurally distinct D(4)-selective agonist with superior oral bioavailability to our first-generation clinical candidate 1a (ABT-724) for the potential treatment of erectile...
2.
Kolasa T, Matulenko M, Hakeem A, Patel M, Mortell K, Bhatia P, et al.
J Med Chem
. 2006 Aug;
49(17):5093-109.
PMID: 16913699
A new series of dopamine D4 receptor agonists, 1-aryl-3-(4-pyridinepiperazin-1-yl)propanone oximes, was designed through the modification of known dopamine D4 receptor agonist PD 168077. Replacement of the amide group with a...
3.
Zheng G, Bhatia P, Kolasa T, Patel M, El Kouhen O, Chang R, et al.
Bioorg Med Chem Lett
. 2006 Jul;
16(18):4936-40.
PMID: 16809035
We have discovered a novel, potent, and selective triazafluorenone series of metabotropic glutamate receptor 1 (mGluR1) antagonists with efficacy in various rat pain models. Pharmacokinetic and pharmacodynamic profiles of these...
4.
Zheng G, Bhatia P, Daanen J, Kolasa T, Patel M, Latshaw S, et al.
J Med Chem
. 2005 Nov;
48(23):7374-88.
PMID: 16279797
SAR (structure-activity relationship) studies of triazafluorenone derivatives as potent mGluR1 antagonists are described. The triazafluorenone derivatives are non-amino acid derivatives and noncompetitive mGluR1 antagonists that bind at a putative allosteric...
5.
Polakowski J, Segreti J, Cox B, Hsieh G, Kolasa T, Moreland R, et al.
Clin Exp Pharmacol Physiol
. 2005 Jan;
31(12):837-41.
PMID: 15659045
1. Activation of dopamine (DA) receptors produces cardiovascular responses such as vasodilation and hypotension. However, knowledge of the role of specific dopamine receptor subtypes (especially D3 and D4) in the...
6.
Patel M, Bell R, Majest S, Henry R, Kolasa T
J Org Chem
. 2004 Oct;
69(21):7058-65.
PMID: 15471453
4,5-Diaryl-1H-pyrazole-3-ol was utilized as a versatile template to synthesize several classes of compounds such as pyrazolo-oxazines 7, pyrazolo-benzooxazines 9, pyrazolo-oxazoles 10, and its analogues 11a-c as potential COX-2 inhibitors. Compounds...
7.
Harris R, Black L, Surapaneni S, Kolasa T, Majest S, Namovic M, et al.
J Pharmacol Exp Ther
. 2004 Jul;
311(3):904-12.
PMID: 15277581
Nonsteriodal anti-inflammatory drugs (NSAIDs) are efficacious for the treatment of pain associated with inflammatory disease. Clinical experience with marketed selective cyclooxygenase-2 (COX-2) inhibitors (celecoxib, rofecoxib, and valdecoxib) has confirmed the...
8.
Altenbach R, Khilevich A, Kolasa T, Rohde J, Bhatia P, Patel M, et al.
J Med Chem
. 2004 May;
47(12):3220-35.
PMID: 15163201
Structure-activity studies were performed on the alpha(1A)-adrenoceptor (AR) selective agonist N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide (4). Compounds were evaluated for binding activity at the alpha(1A), alpha(1b), alpha(1d), alpha(2a), and alpha(2B) subtypes. Functional activity in...